Chemical Watch Expo 2019: Global Chemical Regulations

• Dossier compliance vs Substance evaluation
• Legal implications / Criteria for legal challenges
• Board of Appeal decisions

Claudio Mereu

Partner, EU Regulatory, Fieldfisher LLP, Belgium

• Hazard classification of complex inorganic materials – issues and challenges
• The MeClas tool
• Bioelution testing – principles and applications (with examples)
• Regulatory acceptance of the concept – current status/ongoing work

Kevin Klipsch

Senior Registration Manager, EBRC Consulting GmbH, Germany

In the context of REACH regulation and its implementation, our testing capabilities and expertise permit a complete offer for the registration of a chemical. In particular, INERIS provides toxicological services within a GLP-compliant platform of 1000 m² dedicated to in vivo rodent experiments, including the performance of a battery of in vivo assays, following OECD Test Guidelines (e.g. acute toxicity studies, inhalation toxicology (OECD TG 436, 412, 413) and reproductive toxicology, including neurologic endpoints (OECD TG 422, 443).

Anne Braun

Head of Experimental Toxicology Unit, INERIS

• Which tools are available under the BPR to achieve product authorisation (families, same, consortia) and how can these tools be used to create the best authorisation strategy?
• What are some of the questions companies should ask themselves to determine the appropriate authorisation strategy?
• How will the Endocrine Disruption criteria and Brexit affect biocidal product authorisation strategies?

Eléonore Mullier

Partner, Steptoe, Belgium

Hannah Widemann

Senior Associate, Chemical and Life Sciences, Steptoe & Johnson LLP

• Where the biocides legislation currently is
• The impact it is having on industry
• Expected upcoming changes and challenges

Eleanor Grimes

Regulatory Specialist, UL